SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens Papzimeos. Traders debate whether Voceryqs surgery-free dosing will erode demand or whether Papzimeos can retain an advantage through its commercial head start, established payer access, and full approval.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results sparked debate as strong AWS growth was overshadowed by heavy AI infrastructure spending and worsening free-cash-flow concerns, contributing to pressure on the shares and broader tech sentiment. Traders are split between worries about when the spending will pay off and dip buyers who see resilient cloud demand and point to the stocks sharp rebound.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 earnings report is the main focus, with traders looking beyond a potential beat to whether guidance can sustain its AI growth story amid a broader pullback in tech stocks. Bulls expect strong results and a raised outlook, while bears argue the valuation leaves little room for an ordinary quarter or disappointing guidance.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

Shifting expectations for Fed policy and U.S. interest rates are driving discussion of the dollars moves against major currencies. Traders are split between seeing higher yields and rate-hike bets as support for UUP and warning that fiscal concerns and dollar weakness could undermine the trend.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report is driving attention, with traders weighing concerns about advertising demand, competition and weakness across ad-tech and software stocks. Bulls argue the decline has outpaced the companys fundamentals and are buying the dip, while bears fear the report or outlook could validate further downside.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPaths post-earnings selloff and analyst downgrades following its Investor Day are driving discussion, with traders focused on skepticism about slowing growth and whether its agentic-AI push can translate into stronger revenue. Bulls view the companys orchestration products, cash position, and enterprise potential as undervalued, while bears say the business still needs to prove the strategy commercially.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reaching its 80-event threshold has shifted attention to the upcoming GPS survival-data readout after database lock and final analysis. Traders are sharply divided: bulls expect a meaningful survival benefit, while skeptics question the trials dosing changes, control-arm outcomes and whether the results will support approval.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks quarterly earnings beat expectations and its raised full-year outlook are driving attention, with traders also focusing on the Moderna-partnered melanoma vaccines Phase 3 results and bullish chart momentum. Some investors remain cautious about the vaccines commercial potential and Mercks longer-term patent-cliff exposure.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A third-party photo and commentary identifying POET hardware in Foxconns photonics ecosystem has renewed attention to the FIT collaboration, with traders treating it as validation while debating whether it could lead to production orders; POET has not confirmed new orders. Traders are also weighing reported MarvellLumentum acquisition talks, speculating that optics-sector consolidation could benefit POET as an independent supplier, though others see potential competitive or supply-chain risks.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, have fueled a sharp rally and fresh highs. Traders are broadly bullish on the GLP-1 growth story and retatrutide pipeline, while some question the valuation and point to lower profit guidance from acquisition charges and weaker-than-expected Foundayo sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stonk Trades

TopOptionsAlerts®

BioTechBul

Stephen

nick

$ABCL $MRNA $LLY $REGN $SLS 

👀🔥🚨ABcellera 🔥 🔥!!!
 
-Jefferies initiates AbCellera coverage with a Buy rating 

-The firm highlighted the company’s antibody discovery platform and its clinical pipeline, led by ABCL635, a monthly subcutaneous NK3R antibody for vasomotor symptoms.

-Sets $21 target

StockTwits for iOS

AbCellera Biologics Inc

Moderna Inc

Regeneron Pharmaceuticals, Inc.

Eli Lillys quarterly results beat expectations and its revenue outlook rose on strong Mounjaro and Zepbound demand, fueling a sharp rally and fresh highs. Traders are also weighing the reduced profit outlook tied to acquisition-related charges, elevated valuation, and concerns about competition in oral obesity drugs.

SELLASs Phase 3 REGAL trial reached its 80-death endpoint, triggering final analysis of GPS in AML and focusing discussion on the pending topline results. Bulls read the long trial and possible survival tail as encouraging, while skeptics emphasize that the treatment-arm results remain unknown and raise questions about dosing changes and the control arm; buyout speculation is also prominent.